Phase 2 BRIGHT (an Exploratory Open-Label Tolerability and Efficacy Study of ZYN002 Administered as a Transdermal Gel to Children and Adolescents With Autism Spectrum Disorder): Baseline Characteristics

Helen Heussler,1,2 Michael Duhig,1,2 Terry Hurst,3 Carol O’Neill,4 Wendy Agnese,4 Joseph Palumbo4

1Centre for Clinical Trials in Rare Neurodevelopmental Disorders (CCTRND), Children’s Health Queensland, Brisbane, QLD, Australia; 2Centre for Child Health Research, University of Queensland, Brisbane, QLD, Australia; 3Zynerba Pharmaceuticals, Pty Ltd, Brisbane, QLD, Australia; 4Zynerba Pharmaceuticals, Devon, PA, USA

Presented at the 2020 American Society for Experimental Therapeutics Annual Meeting; March 2-5, 2020: Bethesda, MD, USA.
Disclaimer

• This presentation is for educational purposes only.
• This study was funded by Zynerba Pharmaceuticals.
• TH, CO, WA, and JP are employees of Zynerba Pharmaceuticals.
• HH and MD have received research support from Zynerba Pharmaceuticals.
• Editorial/medical writing support under the guidance of the authors was provided by Madeline Pfau, PhD and David Gibson, PhD, CMPP at ApotheCom, New York, NY USA, and was funded by Zynerba Pharmaceuticals, Devon, PA, USA, in accordance with Good Publication Practice (GPP3) guidelines (Ann Intern Med. 2015;163:461-464.)
BRIGHT Study Design & Treatment

- **ZYN002** is a pharmaceutically manufactured transdermal CBD gel currently in clinical development for the treatment of behavioral symptoms in ASD
- **BRIGHT** is phase 2, open-label, single-center study being conducted in Australia

**Key Inclusion Criteria**
- Male or female patients aged 4 through 17 years
- Confirmed diagnosis of ASD (*DSM-5*)
- CGI-S score ≥4
- ABC-C Irritability Subscale score ≥18

**Primary Objective**
- To evaluate the safety and tolerability of transdermal ZYN002 in the treatment of symptoms of ASD in patients aged 4 through 17 years

**Secondary/Exploratory Objectives**
- To evaluate the efficacy of ZYN002 in the treatment of symptoms of ASD
- To evaluate CBD and THC plasma level exposure
- To identify plasma levels of CBD metabolite(s)

---

*Total daily dose, administered twice daily. Dose is dependent on body weight. The investigator may increase dosage at week 6 in patients with <25% improvement from baseline in ABC-C Irritability Subscale score. ABC-C, Abberant Behavior Checklist–Community; ASD, autism spectrum disorder; CGI-S, Clinical Global Impression–Severity; DSM-5, Diagnostic and Statistical Manual of Mental Disorders, 5th edition; THC, tetrahydrocannabinol.*
Screening and Efficacy Assessments

Schedule of Screening and Efficacy Assessments

<table>
<thead>
<tr>
<th>Screening</th>
<th>Treatment</th>
<th>Extension</th>
<th>EOS/ET</th>
</tr>
</thead>
<tbody>
<tr>
<td>Day – 28 to – 8</td>
<td>Day 1</td>
<td>Week 6</td>
<td>Week 14 Primary efficacy assessment</td>
</tr>
</tbody>
</table>

Key Measures of Baseline Disease Severity

**ABC-C**
- 25-item parent-rated scale assessing anxiety in ASD
- Maximum score is 75, with scores >52 indicating possible clinical anxiety

**ADOS®-2**
- Clinical diagnostic tool assessing social communication and core behaviors of ASD
- Total scores are diagnostic; standardized comparison scores can be used to measure severity
- Comparison scores range from 0-10:
  - <5 = mild ASD; 5-7 = moderate ASD; 8-10 = severe ASD

**PRAS-ASD**
- 58-item caregiver-rated scale measuring behavior across 5 subscales:
  - Irritability/agitation, lethargy/social withdrawal, stereotypic behavior, hyperactivity/noncompliance, inappropriate speech
- Higher scores indicate greater severity of aberrant behavior

---

Baseline Characteristics of BRIGHT Patients

- BRIGHT enrolled 37 male (91.9%) and female (8.1%) patients
- The mean age of patients enrolled in BRIGHT is 9.2 years (range 3-16)
- Most patients are white (75.7%; Aboriginal: 5.4%, Asian: 8.1%; Other: 10.8%)

Most patients had moderate or severe ASD at baseline as measured by ADOS®-2 and DSM-5, and 24.3% of patients had possible clinical anxiety

### Baseline Disease Characteristics of Enrolled Patients

<table>
<thead>
<tr>
<th>Disease Characteristic</th>
<th>BRIGHT patients (N = 37)&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABC-C Irritability Subscale score</td>
<td></td>
</tr>
<tr>
<td>Mean (range)</td>
<td>30.0 (18-43)</td>
</tr>
<tr>
<td>PRAS-ASD score</td>
<td></td>
</tr>
<tr>
<td>Mean (range)</td>
<td>40.9 (21-68)</td>
</tr>
<tr>
<td>&gt;52, n (%)</td>
<td>9 (24.3)</td>
</tr>
<tr>
<td>DSM-5 severity level&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Level 1 (mild), n (%)</td>
<td>3 (8.1)</td>
</tr>
<tr>
<td>Level 2 (moderate), n (%)</td>
<td>15 (40.5)</td>
</tr>
<tr>
<td>Level 3 (severe), n (%)</td>
<td>19 (51.4)</td>
</tr>
<tr>
<td>ADOS®-2 total score</td>
<td></td>
</tr>
<tr>
<td>Mean (range)</td>
<td>17.5 (7-25)</td>
</tr>
<tr>
<td>ADOS®-2 comparison score</td>
<td></td>
</tr>
<tr>
<td>Mean (range)</td>
<td>7.5 (4-10)</td>
</tr>
<tr>
<td>&lt;5, n (%)</td>
<td>2 (5.6)</td>
</tr>
<tr>
<td>5-7, n (%)</td>
<td>19 (52.8)</td>
</tr>
<tr>
<td>8-10, n (%)</td>
<td>15 (41.7)</td>
</tr>
</tbody>
</table>

<sup>a</sup>N=37 for all characteristics except ADOS®-2 total and comparison scores, for which data is missing from one patient (n=36).

<sup>b</sup>DSM-5 severity levels are based on degree of social communication impairment and behavioral flexibility. The levels indicate patients “requiring support” (level 1), “requiring substantial support” (level 2), and “requiring very substantial support” (level 3).

Conclusions

• BRIGHT is an ongoing, exploratory, phase 2, open-label study to evaluate the safety, tolerability, and efficacy of ZYN002 in children and adolescents with ASD, a patient population with high unmet needs
• BRIGHT enrolled a broad and inclusive patient population and was enriched for disease severity to avoid floor effects on outcome measures
• Baseline characteristics indicate a patient population with predominantly moderate-to-severe ASD, with a high burden of anxiety
• Topline results from BRIGHT will be available in 2Q2020

ASD, autism spectrum disorder.